Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 7/2015

01-07-2015 | Original Scientific Report

VEGF-D and A Preoperative Serum Levels Predict Nodal and Distant Metastases in Differentiated Thyroid Cancer Patients

Authors: Chieh-Wen Lai, Quan-Yang Duh, Chuang-Wei Chen, Fu-Jie Chuang, Yao-Jen Chang, Ming-Tsan Lin, Ming-Hsun Wu

Published in: World Journal of Surgery | Issue 7/2015

Login to get access

Abstract

Background

Preoperative tumor aggressiveness biomarkers may help surgeons decide the extent of an operation. However, whether serum angiogenetic factors can be used to predict the prognosis of patients with differentiated thyroid cancer is still unclear.

Methods

Seventy-six DTC patients were prospectively recruited. Preoperative serum samples were collected and measured for Tie-2, Ang-1, Ang-2, VEGF-A, and VEGF-D levels. The potential correlations between their serum levels and clinicopathologic features as well as their prognoses were analyzed.

Results

Older age (>45 years old) and higher VEGF-A serum levels were independent predictors of extrathyroidal extension. The VEGF-D serum level was an independent factor for lymph node metastases and VEGF-A was an independent factor for distant metastases. None of these serum angiogenetic factors were significantly different between patients who were disease free and those with recurrences. The presence of lymph node metastases was the only independent factor for recurrence over the 2-year follow-up.

Conclusion

Preoperative serum VEGF-A and VEGF-D levels were significantly elevated in DTC patients with distant and lymph node metastases. These findings, when combined with other clinicopathological factors, may help in surgical decisions.
Literature
1.
2.
Alitalo K, Mohla S, Ruoslahti E (2004) Lymphangiogenesis and cancer: meeting report. Cancer Res 64:9225–9229PubMedCrossRef
3.
Alitalo K, Carmeliet P (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1:219–227PubMedCrossRef
4.
Park JH, Park KJ, Kim YS et al (2007) Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132:200–206PubMedCrossRef
5.
Yalcin M, Dyskin E, Lansing L et al (2010) Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 95:1972–1980PubMedCrossRef
6.
Wray CJ, Rilo HL, Ahmad SA (2004) Colon cancer angiogenesis and antiangiogenic therapy. Expert Opin Investig Drugs 13:631–641PubMedCrossRef
7.
Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10:165–177PubMedCrossRef
8.
9.
Lohela M, Bry M, Tammela T, Alitalo K (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21:154–165PubMedCrossRef
10.
Huang H, Bhat A, Woodnutt G, Lappe R (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10:575–585PubMedCrossRef
11.
Saharinen P, Eklund L, Pulkki K et al (2011) VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 17:347–362PubMedCrossRef
12.
Peters KG, Kontos CD, Lin PC et al (2004) Functional significance of Tie2 signaling in the adult vasculature. Recent Prog Horm Res 59:51–71PubMedCrossRef
13.
Abdallah A, Belal M, El Bastawisy A, Gaafar R (2014) Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer. Oncol Lett 7:2121–2129PubMedCentralPubMed
14.
Yang B, Gu W, Peng B et al (2012) High level of circulating endothelial progenitor cells positively correlates with serum vascular endothelial growth factor in patients with renal cell carcinoma. J Urol 188:2055–2061PubMedCrossRef
15.
Jelkmann W (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47:617–623PubMed
16.
Sobin LH, Fleming ID (1997) TNM Classification of Malignant Tumors, 5th edition . Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80:1803–1804
17.
18.
Salcedo X, Medina J, Sanz-Cameno P et al (2005) The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 42:696–701PubMedCrossRef
19.
Bunone G, Vigneri P, Mariani L et al (1999) Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155:1967–1976PubMedCentralPubMedCrossRef
20.
21.
Viglietto G, Maglione D, Rambaldi M et al (1995) Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569–1579PubMed
22.
Yu XM, Lo CY, Lam AK et al (2008) Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg 247:483–489PubMedCrossRef
23.
de Araujo-Filho VJ, Alves VA, de Castro IV et al (2009) Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma. Thyroid 19:1233–1237PubMedCrossRef
24.
Soh EY, Duh QY, Sobhi SA et al (1997) Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82:3741–3747PubMed
25.
Klein M, Vignaud JM, Hennequin V et al (2001) Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86:656–658PubMedCrossRef
26.
Zhou ZH, Cui XN, Xing HG et al (2013) Changes and prognostic value of serum vascular endothelial growth factor in patients with differentiated thyroid cancer. Med Princ Pract 22:24–28PubMedCrossRef
27.
Karaca Z, Tanriverdi F, Unluhizarci K et al (2011) VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 164:277–284PubMedCrossRef
28.
Bassiouny AR, Zaky A, Neenaa HM (2010) Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients. Ann Hepatol 9:410–418PubMed
29.
Kwon KA, Kim SH, Oh SY et al (2010) Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 10:203PubMedCentralPubMedCrossRef
30.
Villarejo-Campos P, Padilla-Valverde D, Martin RM et al (2013) Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer. Clin Transl Oncol 15:265–270PubMedCrossRef
31.
Ringel MD, Anderson J, Souza SL et al (2001) Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol 14:289–296PubMedCrossRef
32.
Noguchi S, Murakami N, Yamashita H et al (1998) Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg 133:276–280PubMedCrossRef
33.
Mazzaferri EL, Young RL (1981) Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511–518PubMedCrossRef
34.
Hughes CJ, Shaha AR, Shah JP, Loree TR (1996) Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck 18:127–132PubMedCrossRef
35.
Jukkola A, Bloigu R, Ebeling T et al (2004) Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer 11:571–579PubMedCrossRef
36.
Forest VI, Clark JR, Ebrahimi A et al (2011) Central compartment dissection in thyroid papillary carcinoma. Ann Surg 253:123–130PubMedCrossRef
37.
Shen WT, Ogawa L, Ruan D et al (2010) Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit. Surgery 148:398–403PubMedCrossRef
38.
Alitalo K, Tammela T, Petrova TV (2005) Lymphangiogenesis in development and human disease. Nature 438:946–953PubMedCrossRef
39.
Nakamura Y, Yasuoka H, Tsujimoto M et al (2003) Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer. Clin Cancer Res 9:5313–5317PubMed
40.
Yasuoka H, Nakamura Y, Zuo H et al (2005) VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 18:1127–1133PubMedCrossRef
41.
Tanaka K, Kurebayashi J, Sonoo H et al (2002) Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues. Surg Today 32:761–768PubMedCrossRef
42.
Lai CW, Chen KY, Hung CS et al (2011) Serum vascular endothelial growth factor-D levels correlate with cervical lymph node metastases in papillary thyroid carcinoma. Growth Factors 29:57–62PubMedCrossRef
43.
Nersita R, Matrone A, Klain M et al (2012) Decreased serum vascular endothelial growth factor-D levels in metastatic patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 76:142–146CrossRef
44.
Niedzwiecki S, Stepien T, Kopec K et al (2006) Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers. Cytokine 36:291–295PubMedCrossRef
45.
Mitsutake N, Namba H, Takahara K et al (2002) Tie-2 and angiopoietin-1 expression in human thyroid tumors. Thyroid 12:95–99PubMedCrossRef
46.
Hsueh C, Lin JD, Wu IC et al (2011) Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma. J Surg Oncol 103:395–399PubMedCrossRef
47.
Xing M, Westra WH, Tufano RP et al (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373–6379PubMedCrossRef
48.
Kebebew E, Weng J, Bauer J et al (2007) The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466–470 discussion 470–461PubMedCentralPubMedCrossRef
49.
Durante C, Tallini G, Puxeddu E et al (2011) BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. Eur J Endocrinol 165:455–463PubMedCrossRef
50.
Hughes DT, Miller BS, Cohen MS et al (2014) Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin. Ann Surg Oncol 21:1647–1652PubMedCrossRef
51.
Ito Y, Kudo T, Kobayashi K et al (2012) Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg 36:1274–1278. doi:10.​1007/​s00268-012-1423-5 PubMedCrossRef
52.
Mondul AM, Rager HC, Kopp W et al (2011) Supplementation with alpha-tocopherol or beta-carotene reduces serum concentrations of vascular endothelial growth factor-D, but Not -A or -C, in male smokers. J Nutr 141:2030–2034PubMedCentralPubMedCrossRef
Metadata
Title
VEGF-D and A Preoperative Serum Levels Predict Nodal and Distant Metastases in Differentiated Thyroid Cancer Patients
Authors
Chieh-Wen Lai
Quan-Yang Duh
Chuang-Wei Chen
Fu-Jie Chuang
Yao-Jen Chang
Ming-Tsan Lin
Ming-Hsun Wu
Publication date
01-07-2015
Publisher
Springer International Publishing
Published in
World Journal of Surgery / Issue 7/2015
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-015-3016-6

Other articles of this Issue 7/2015

World Journal of Surgery 7/2015 Go to the issue

Original Scientific Report

A Prospective Randomized Controlled Trial of the Laryngeal Mask Airway Versus the Endotracheal Intubation in the Thyroid Surgery: Evaluation of Postoperative Voice, and Laryngopharyngeal Symptom

Original Scientific Report

Preoperative 11C-Methionine PET/CT Enables Focussed Parathyroidectomy in MIBI-SPECT Negative Parathyroid Adenoma

Erratum

Erratum to: Age and Obesity are Independent Predictors of Bile Duct Injuries in Patients Undergoing Laparoscopic Cholecystectomy

Surgical Symposium Contribution

Achalasia: A to Z

Original Scientific Report

Aerosolized Intraperitoneal Local Anesthetic for Laparoscopic Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial

Original Scientific Report

Myths and Misinformation About Gunshot Wounds may Adversely Affect Proper Treatment